FindTrial
Sign In

ABBV-927

DRUG4 trials

Sponsors

AbbVie

Conditions

Advanced Solid TumorsAdvanced Solid Tumors CancerCancerHead and Neck CancerMetastatic Solid TumorsNon-small-cell-lung-cancer (NSCLC)Pancreatic CancerTriple-Negative Breast Cancer (TNBC)

Phase 1

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors
Active, not recruitingNCT02988960
AbbVieAdvanced Solid Tumors Cancer
Start: 2017-02-22End: 2026-09-30Updated: 2026-01-09
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
TerminatedNCT03818542
AbbVieHead and Neck Cancer
Start: 2020-01-22End: 2020-09-23Updated: 2020-12-31
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
Active, not recruitingNCT03893955
AbbVieAdvanced Solid Tumors, Cancer, Metastatic Solid Tumors +2
Start: 2019-05-21End: 2026-03-31Target: 150Updated: 2025-08-12
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis
TerminatedNCT04807972
AbbViePancreatic Cancer
Start: 2021-05-28End: 2024-03-25Updated: 2025-01-07

Related Papers

Abstract CT246: Phase 1b/2 study of giloralimab in combination with modified FOLFIRINOX with or without budigalimab in patients with untreated metastatic pancreatic cancer
Cancer Research2022-06-15
A phase I study of CD40 agonist ABBV-927 plus OX40 agonist ABBV-368 with or without the PD-1 inhibitor budigalimab in patients with advanced solid tumors.
Journal of Clinical Oncology2020-05-206 citations